> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Allogene ‘Fast Track’ for Renal Cell Carcinoma Drug
- URL: https://www.fdaweb.com/allogene-fast-track-for-renal-cell-carcinoma-drug/
- Published: 2022-03-11T12:00:00.000Z
- Updated: 2026-09-14T17:36:13.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151348

FDA has granted Allogene Therapeutics a fast track designation for its allogeneic CAR T product (ALLO-316) for treating patients with advanced or metastatic clear cell renal cell carcinoma (RCC) in those who’ve failed standard RCC therapies.

“ALLO-316 targets CD70, which is highly expressed in RCC with limited normal tissue expression, making it an attractive CAR T,” the company says. “CD70 is also selectively expressed in several cancers, creating the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors.” The company is conducting the Phase 1 TRAVERSE trial to evaluate the safety, tolerability, and activity of ALLO-316 in patients with advanced or metastatic clear cell RCC.